Circulating IGF-I: New perspectives for a new century

Trends in Endocrinology and Metabolism

Volumn 10, Issue 4, 1999, Pages 136-141

  Rosen, Clifford J ^a   Pollak, Michael ^b  

^a JACKSON LABORATORY   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; BONE REMODELING; CANCER; CANCER RISK; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HORMONAL CARCINOGENESIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE RECEPTOR INTERACTION; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033014473     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00126-X     Document Type: Review

References (58)

1. Salmon W.D., Daughaday W.H. A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J. Lab. Clin. Med. 49:1957;825-836.
2. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev.1:1995;3-34.
3. Rudman D., Feller A.G., Nelgrag H.S. Effect of human GH in men over age 60. New Engl. J. Med. 323:1990;52-60.
4. Delhanty P.J., Baxter R.C. Cloning and characterization of the rat gene for the acid-labile subunit of the insulin-like growth factor binding protein complex. J. Mol. Endocrinol. 19:1997;267-277.
5. Binouz M. IGF-binding protein-3 and acid-labile subunit: what is the pecking order? Eur. J. Endocrinol. 137:1997;605-609.
6. Twigg S.M., Baxter R.C. IGF binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J. Biol. Chem. 273:1998;6074-6079.
7. Holman S.R., Baxter R.C. IGFBP-3: factors affecting binary and ternary complex formation. Growth Regul. 6:1996;42-47.
8. Coverley J.A., Baxter R.C. Phosphorylation of IGFBPs. Mol. Cell. Endocrinol. 128:1997;1-5.
9. Mohan S., Baylink D.J. Autocrine and paracrine aspects of bone metabolism. Growth Genet. Horm. 6:1990;1-9.
10. Rosen C.J., Conover C. GH/IGF-I axis in aging: a summary of a NIA-sponsored symposium. J. Clin. Endocrinol. Metab. 82:1997;3919-3922.
11. Nunn S.E., Beers Gibson T., Roopmathy R., Cohen P. Regulation of prostate cell growth by the IGFBPs and their proteases. Endocrine. 7:1997;115-118.
12. Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr. Rev. 15:1994;80-101.
13. Kao P.C., Matheny A.P., Lang C.A. IGF-I comparisons in healthy twin children. J. Clin. Endocrinol. Metab. 78:1994;310-312.
14. Harrela M.et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1 and IGFBP-3. J. Clin. Invest. 98:1996;2612-2615.
15. Rosen C.J.et al. Circulating and skeletal IGF-I concentrations in two inbred strains of mice with different bone densities. Bone. 21:1997;217-223.
16. Rosen C.J.et al. Association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of BMD. J. Clin. Endocrinol. Metab. 83:1998;2286-2290.
17. Ludwig T., Eggenschwiler J., Fisher P., D'Ercole A.J., Davenport M.L., Efstratiadis A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev. Biol. 177:1996;517-535.
18. Baserga R., Resnicoff M., Dews M. The IGF-I receptor and cancer. Endocrine. 7:1997;99-102.
19. LeRoith D., Parriza M., Blakesley V.A. The IGF-I receptor and apoptosis. Endocrine. 7:1997;103-105.
20. Sell C., Baserga R., Rubin R. IGF-I and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55:1995;303-306.
21. Rozen F., Zhang J., Pollak M. Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J. Oncol. 13:1998;865-869.
22. Rosen C.J., Donahue L.R., Hunter S.J. IGFs and bone: the osteoporosis connection. Proc. Soc. Exp. Biol. Med. 206:1994;83-102.
23. Ng S.T., Zhou J., Adesanya O.O., Wang J., LeRoith D., Bondy C.A. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat. Med. 3:1997;1141-1144.
24. Neuberg M., Buckbinder L., Seizinger B., Kley N. The p53/IGF-I receptor axis in the regulation of programmed cell death. Endocrine. 7:1997;107-109.
25. Oh Y., Muller H., Lamson G., Rosenfeld R.G. IGF-independent action of IGFBP-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J. Biol. Chem. 268:1993;14964-14971.
26. Oh Y. IGFBPs and neoplastic models. Endocrine. 7:1997;111-113.
27. Pollak M.et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82:1990;1693-1697.
28. Huynh H.T., Yang X.F., Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 271:1996;1016-1021.
29. Huynh H.T., Yang X.F., Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ. 7:1996;1501-1506.
30. Nickerson T., Pollak M., Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology. 139:1998;807-810.
31. Bellantoni M.F., Vittone J., Campfield A.T., Bass K.M., Harman S.M., Blackman M.R. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like factor I axis in younger and older postmenopausal women: a clinical research center study. J. Clin. Endocrinol. Metab. 81:1996;2848-2853.
32. Rosen C.J., Verault C.A., Raymond J.P., Hoffman R.M., Craig W.Y. IGF-I: a risk factor for restenosis after coronary angioplasty. Circulation. 96:1997;3305.
33. Chan J.M.et al. Plasma IGF-I and prostate cancer risk: a prospective study. Science. 279:1998;563-566.
34. Hankinson S.E.et al. Circulating concentrations of IGF-I and the risk of breast cancer. Lancet. 351:1998;1593-1596.
35. Ma J.et al. A prospective study of plasma levels of IGF-I, IGFBP-3 and colon cancer risk among men. J. Natl. Cancer Inst. (in press).
36. Wolk A.et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90:1998;911-915.
37. Jorgenson J.O., Pedersen S.A., Thuesen L. Beneficial effects of GH treatment in GH-deficient adults. Lancet. 1:1989;1221-1225.
38. Rudman D. Growth hormone, body composition and aging. J. Am. Geriatr. Soc. 3:1985;800-807.
39. Boonen S.et al. Age-associated decline in human femoral neck cortical and trabecular content of IGF-I: potential implications for age-related osteoporosis. Calcif. Tissue Int. 61:1997;173-178.
40. Nicholas V.et al. Age-related declines in IGF-I and TGF-beta in femoral cortical bone from men and women. J. Clin. Endocrinol. Metab. 78:1994;1011-1016.
41. Ravn K., Overgaard K., Spencer E.M., Christiansen C. IGF-I and IGF-II in healthy women with/without established osteoporosis. Eur. J. Endocrinol. 132:1995;313-319.
42. Langlois J.A.et al. The association between IGF-I and bone mineral density in women and men: the Framingham heart study. J. Clin. Endocrinol. Metab. 83:1998;4257-4263.
43. Brixen K., Nielsen H.K., Mosekilde L., Flyvbjerg A. A short course of recombinant human GH treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J. Bone Miner. Res. 5:1990;609-615.
44. Marcus R. Skeletal effects of GH and IGF-I in adults. Endocrine. 7:1997;52-55.
45. Thompson J.L., Butterfield G.E., Marcus R. The effects of recombinant rhIGF-I and GH on body composition in elderly women. J. Clin. Endocrinol. Metab. 80:1995;1845-1852.
46. Maclean D., Kiel D.P., Rosen C.J. Low dose rhGH for frail elders stimulates bone turnover in a dose dependent manner. J. Bone Miner. Res. 10, S1:1995;458.
47. Zhang Y.et al. Bone mass and the risk of breast cancer among postmenopausal women. New Engl. J. Med. 336:1997;611-617.
48. Hankinson S.E.et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 90:1998;1292-1299.
49. Juul A., Main K., Blum W.F., Lindholm J., Ranke M.B., Skakkebaek N.E. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP)-1, 2 and 3 decreases with age in healthy adults and is increased in acromegalic patients. Clin. Endocrinol. 41:1994;85-93.
50. Yang X.F., Beamer W., Huynh H.T., Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res. 56:1996;1509-1511.
51. Torrisi R.et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int. J. Cancer. 76:1998;787-790.
52. Guvakova M.A., Surmacz E. Tamoxifen interferes with the IGF-I receptor signaling pathway in breast cancer cells. Cancer Res. 57:1997;2606-2610.
53. Dunn S.E.et al. Dietary restriction reduces IGF-I levels which modulates apoptosis, cell proliferation and tumor progression in p53 deficient mice. Cancer Res. 57:1997;4667-4672.
54. Zhang L.et al. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
55. Tritos N.A., Mantzoros C.S. Recombinant human growth hormone: old and novel uses. Am. J. Med. 105:1998;44-57.
56. Papadakis M.A., Grady D., Black D., Tremey M.J., Goding G.A.W., Grunfeld C. GH replacement in healthy older men improves body composition but not functional activity. Ann. Intern. Med. 124:1996;708-716.
57. Yarasheshki K.E., Zachwieja J.J., Campbell J.A., Bier D.M. Effects of GH and resistance exercise on muscle growth and strength in older men. Am. J. Physiol. 268:1995;E268.
58. Kiel D.P., Puhl J., Rosen C.J., Berg K., Murphy J.B., MacLean D.B. Lack of an association between IGF-I, and body composition, muscle strength, physical performance or self reported mobility among older persons with functional limitations. J. Am. Geriatr. Soc. 46:1998;822-828.